aspirin has been researched along with Bipolar Disorder in 20 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Bipolar Disorder: A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This clinical evidence is consistent with the hypothesis that low-dose chronic aspirin and celecoxib, which can inhibit COX-2 and enter brain, can be repurposed in bipolar disorder to enhance mood stabilizer effects on arachidonic acid metabolism and neurotransmission." | 9.12 | Aspirin and celecoxib may help to rectify a neurotransmission imbalance in bipolar disorder. ( Rapoport, SI, 2021) |
| "We reviewed randomized controlled trials (RCTs) and population studies to examine whether celecoxib, a selective cyclooxygenase (COX)-2 inhibitor, and acetylsalicylate (aspirin), a COX-1 and COX-2 inhibitor and acetylator, were useful in bipolar disorder patients on mood stabilizers." | 9.05 | THERAPEUTIC TARGETING OF BRAIN ARACHIDONIC ACID CASCADE IN BIPOLAR DISORDER BY LOW DOSE ASPIRIN AND CELECOXIB. ( Hibbeln, JR; Rapoport, SI, 2020) |
| "Antipsychotic drugs plus aspirin (acetylsalicylic acid), which targets prostaglandin-endoperoxide synthase 1 (PTGS1: COX1), improved therapeutic outcomes when treating schizophrenia." | 7.88 | Studies on Prostaglandin-Endoperoxide Synthase 1: Lower Levels in Schizophrenia and After Treatment with Antipsychotic Drugs in Conjunction with Aspirin. ( Dean, B; Gibbons, A; Gogos, A; Scarr, E; Thomas, E; Udawela, M, 2018) |
| "Given evidence of chronic inflammation in bipolar disorder (BD), we tested the efficacy of aspirin and minocycline as augmentation therapy for bipolar depression." | 5.27 | Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial. ( Drevets, D; Drevets, WC; Gleason, O; Macaluso, M; Meyer, M; Misaki, M; Preskorn, SH; Savitz, JB; Teague, TK; Wurfel, BE; Yates, W, 2018) |
| "This clinical evidence is consistent with the hypothesis that low-dose chronic aspirin and celecoxib, which can inhibit COX-2 and enter brain, can be repurposed in bipolar disorder to enhance mood stabilizer effects on arachidonic acid metabolism and neurotransmission." | 5.12 | Aspirin and celecoxib may help to rectify a neurotransmission imbalance in bipolar disorder. ( Rapoport, SI, 2021) |
| "We reviewed randomized controlled trials (RCTs) and population studies to examine whether celecoxib, a selective cyclooxygenase (COX)-2 inhibitor, and acetylsalicylate (aspirin), a COX-1 and COX-2 inhibitor and acetylator, were useful in bipolar disorder patients on mood stabilizers." | 5.05 | THERAPEUTIC TARGETING OF BRAIN ARACHIDONIC ACID CASCADE IN BIPOLAR DISORDER BY LOW DOSE ASPIRIN AND CELECOXIB. ( Hibbeln, JR; Rapoport, SI, 2020) |
| " We systematically used Danish nation-wide population-based registers to investigate whether continued use of non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs), low-dose aspirin, high-dose aspirin, statins, allopurinol, and angiotensin agents decrease the rate of incident mania/bipolar disorder." | 3.91 | New drug candidates for bipolar disorder-A nation-wide population-based study. ( Andersen, PK; Berk, M; Ekstrøm, CT; Gerds, TA; Kessing, LV; Rytgaard, HC, 2019) |
| "Antipsychotic drugs plus aspirin (acetylsalicylic acid), which targets prostaglandin-endoperoxide synthase 1 (PTGS1: COX1), improved therapeutic outcomes when treating schizophrenia." | 3.88 | Studies on Prostaglandin-Endoperoxide Synthase 1: Lower Levels in Schizophrenia and After Treatment with Antipsychotic Drugs in Conjunction with Aspirin. ( Dean, B; Gibbons, A; Gogos, A; Scarr, E; Thomas, E; Udawela, M, 2018) |
| "Neuropsychiatric disorders place a very high burden on the global health and economy." | 2.61 | Acetylsalicylic acid and its metabolite gentisic acid may act as adjunctive agents in the treatment of psychiatric disorders. ( Altinoz, MA; Ozpinar, A, 2019) |
| "In many individuals with major neuropsychiatric disorders including depression, bipolar disorder and schizophrenia, their disease characteristics are consistent with a neuroprogressive illness." | 2.49 | Putative neuroprotective agents in neuropsychiatric disorders. ( Anderson, G; Berk, M; Dean, OM; Dodd, S; Maes, M; Moylan, S, 2013) |
| "The pharmacologic treatment of schizophrenia and bipolar disorder leaves much to be desired." | 2.48 | Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas. ( Davis, JM; Torrey, EF, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (15.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (65.00) | 24.3611 |
| 2020's | 3 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Philipsen, L | 1 |
| Würtz, N | 1 |
| Polcwiartek, C | 1 |
| Kragholm, KH | 1 |
| Torp-Pedersen, C | 1 |
| Nielsen, RE | 1 |
| Jensen, SE | 1 |
| Attar, R | 1 |
| Altinoz, MA | 1 |
| Ozpinar, A | 1 |
| Rapoport, SI | 3 |
| Hibbeln, JR | 1 |
| Savitz, JB | 1 |
| Teague, TK | 1 |
| Misaki, M | 1 |
| Macaluso, M | 1 |
| Wurfel, BE | 1 |
| Meyer, M | 1 |
| Drevets, D | 1 |
| Yates, W | 1 |
| Gleason, O | 1 |
| Drevets, WC | 1 |
| Preskorn, SH | 1 |
| Dean, B | 1 |
| Gibbons, A | 1 |
| Gogos, A | 1 |
| Udawela, M | 1 |
| Thomas, E | 1 |
| Scarr, E | 1 |
| Bauer, IE | 1 |
| Green, C | 1 |
| Colpo, GD | 1 |
| Teixeira, AL | 1 |
| Selvaraj, S | 1 |
| Durkin, K | 1 |
| Zunta-Soares, GB | 1 |
| Soares, JC | 1 |
| Kessing, LV | 1 |
| Rytgaard, HC | 1 |
| Gerds, TA | 1 |
| Berk, M | 2 |
| Ekstrøm, CT | 1 |
| Andersen, PK | 1 |
| Saroukhani, S | 1 |
| Emami-Parsa, M | 1 |
| Modabbernia, A | 1 |
| Ashrafi, M | 1 |
| Farokhnia, M | 1 |
| Hajiaghaee, R | 1 |
| Akhondzadeh, S | 1 |
| Riesselman, A | 1 |
| Strobl, B | 1 |
| Cooley, AT | 1 |
| de Leon, J | 1 |
| Fond, G | 2 |
| Girerd, N | 2 |
| Clavel, F | 1 |
| Tamouza, R | 1 |
| Leboyer, M | 2 |
| Macgregor, A | 1 |
| Bazinet, RP | 1 |
| Stolk, P | 1 |
| Souverein, PC | 1 |
| Wilting, I | 1 |
| Leufkens, HG | 1 |
| Klein, DF | 1 |
| Heerdink, ER | 1 |
| Torrey, EF | 1 |
| Davis, JM | 1 |
| Dodd, S | 1 |
| Maes, M | 1 |
| Anderson, G | 1 |
| Dean, OM | 1 |
| Moylan, S | 1 |
| Higgins, RM | 1 |
| Connolly, JO | 1 |
| Hendry, BM | 1 |
| Ragheb, MA | 1 |
| Lereboullet, J | 1 |
| Rosa, A | 1 |
| Olivier-Martin, R | 1 |
| Friedman, D | 1 |
| Moskowitz, MD | 1 |
| Rosen, M | 1 |
| Rossman, M | 1 |
| Sheppard, C | 1 |
| Merlis, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-blind Randomized Placebo-controlled Study of Aspirin and N-acetyl Cysteine as Adjunctive Treatments for Bipolar Disorder Patients (SMRI 11T-009)[NCT01797575] | Phase 2 | 38 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The MADRS is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. A higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The questionnaire includes questions on the following symptoms: 1. Apparent sadness; 2. Reported sadness; 3. Inner tension; 4. Reduced sleep; 5. Reduced appetite; 6. Concentration difficulties; 7. Lassitude; 8. Inability to feel; 9. Pessimistic thoughts; and 10. Suicidal thoughts. This 30% MADRS reduction was analyzed in addition to initial outcome measures of 50% MADRS reduction due to the smaller than expected study sample size. (NCT01797575)
Timeframe: Received drug for 8 weeks during week 0 to week 8 of the study
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin and NAC | 3 |
| Aspirin | 2 |
| N-Acetyl Cysteine (NAC) | 6 |
| Placebo | 7 |
The MADRS is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. A higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The questionnaire includes questions on the following symptoms: 1. Apparent sadness; 2. Reported sadness; 3. Inner tension; 4. Reduced sleep; 5. Reduced appetite; 6. Concentration difficulties; 7. Lassitude; 8. Inability to feel; 9. Pessimistic thoughts; and 10. Suicidal thoughts. This 30% MADRS reduction was analyzed in addition to initial outcome measures of 50% MADRS reduction due to the smaller than expected study sample size. (NCT01797575)
Timeframe: Received drug for 8 weeks during week 9 to week 16 of the study
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin and NAC | 4 |
| Aspirin | 3 |
| N-Acetyl Cysteine (NAC) | 3 |
| Placebo | 4 |
The MADRS is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. A higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The questionnaire includes questions on the following symptoms: 1. Apparent sadness; 2. Reported sadness; 3. Inner tension; 4. Reduced sleep; 5. Reduced appetite; 6. Concentration difficulties; 7. Lassitude; 8. Inability to feel; 9. Pessimistic thoughts; and 10. Suicidal thoughts. (NCT01797575)
Timeframe: Received drug for 8 weeks during week 0 to week 8 of the study
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin and NAC | 3 |
| Aspirin | 2 |
| N-Acetyl Cysteine (NAC) | 5 |
| Placebo | 6 |
The MADRS is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. A higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The questionnaire includes questions on the following symptoms: 1. Apparent sadness; 2. Reported sadness; 3. Inner tension; 4. Reduced sleep; 5. Reduced appetite; 6. Concentration difficulties; 7. Lassitude; 8. Inability to feel; 9. Pessimistic thoughts; and 10. Suicidal thoughts. (NCT01797575)
Timeframe: Received drug for 8 weeks during week 9 to week 16 of the study
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin and NAC | 3 |
| Aspirin | 1 |
| N-Acetyl Cysteine (NAC) | 3 |
| Placebo | 4 |
C-reactive protein (CRP) levels are blood test markers of inflammation. Higher CRP corresponds with higher levels of inflammation. CRP is measured in milligrams per liter. (NCT01797575)
Timeframe: baseline, week 8, week 16
| Intervention | milligrams per liter (Mean) | ||
|---|---|---|---|
| CRP at Baseline | CRP at Week 8 | CRP at Week 16 | |
| Aspirin | 6.85 | 6.82 | 10.76 |
| Aspirin and NAC | 5.1 | 17.02 | 9.39 |
| N-acetyl-cysteine | 17.65 | 41.09 | 17.69 |
| Sugar Pill | 17.30 | 7.4 | 13.10 |
Interleukin 6 (IL-6) is an interleukin that acts as a pro-inflammatory cytokine and an anti-inflammatory myokine. IL-6 is measured in picograms (pg) per milliliter (mL). Elevated interleukin-6 indicates potential immune system dysregulation and increased inflammation. (NCT01797575)
Timeframe: baseline, week 8, week 16
| Intervention | picograms per milliliter (Mean) | ||
|---|---|---|---|
| IL-6 at Baseline | IL-6 at Week 8 | IL-6 at Week 16 | |
| Aspirin | 1.27 | .78 | .90 |
| Aspirin and NAC | .85 | 1.76 | 1.72 |
| N-acetyl-cysteine | 3.22 | 3.53 | 2.6 |
| Sugar Pill | 2.3 | 1.87 | 1.71 |
6 reviews available for aspirin and Bipolar Disorder
| Article | Year |
|---|---|
Acetylsalicylic acid and its metabolite gentisic acid may act as adjunctive agents in the treatment of psychiatric disorders.
Topics: Anti-Inflammatory Agents; Antioxidants; Aspirin; Bipolar Disorder; Gentisates; Humans; Inflammation; | 2019 |
THERAPEUTIC TARGETING OF BRAIN ARACHIDONIC ACID CASCADE IN BIPOLAR DISORDER BY LOW DOSE ASPIRIN AND CELECOXIB.
Topics: Arachidonic Acid; Aspirin; Bipolar Disorder; Brain; Celecoxib; Humans; Randomized Controlled Trials | 2020 |
Aspirin and celecoxib may help to rectify a neurotransmission imbalance in bipolar disorder.
Topics: Animals; Antimanic Agents; Aspirin; Bipolar Disorder; Celecoxib; Humans; Rats; Synaptic Transmission | 2021 |
Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Tricyclic; An | 2012 |
Putative neuroprotective agents in neuropsychiatric disorders.
Topics: Animals; Aspirin; Bipolar Disorder; Depressive Disorder; Humans; Lithium; Mental Disorders; Nerve Gr | 2013 |
Alkalinization and hemodialysis in severe salicylate poisoning: comparison of elimination techniques in the same patient.
Topics: Acute Disease; Adult; Alcoholic Intoxication; Aspirin; Bipolar Disorder; Drug Overdose; Epilepsy, To | 1998 |
4 trials available for aspirin and Bipolar Disorder
| Article | Year |
|---|---|
Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial.
Topics: Adult; Antidepressive Agents; Aspirin; Bipolar Disorder; C-Reactive Protein; Dose-Response Relations | 2018 |
A Double-Blind, Randomized, Placebo-Controlled Study of Aspirin and N-Acetylcysteine as Adjunctive Treatments for Bipolar Depression.
Topics: Acetylcysteine; Adult; Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 2018 |
Aspirin for treatment of lithium-associated sexual dysfunction in men: randomized double-blind placebo-controlled study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bipolar Disorder; Double-Blind Method; Huma | 2013 |
Effects of chlormezanone on anxiety and tension: a double blind study.
Topics: Adolescent; Adult; Aged; Anxiety; Anxiety Disorders; Aspirin; Bipolar Disorder; Chlormezanone; Clini | 1966 |
10 other studies available for aspirin and Bipolar Disorder
| Article | Year |
|---|---|
Time trends of coronary procedures, guideline-based drugs and all-cause mortality following acute coronary syndrome in patients with bipolar disorder.
Topics: Acute Coronary Syndrome; Aspirin; Bipolar Disorder; Humans; Lipids; Percutaneous Coronary Interventi | 2023 |
Studies on Prostaglandin-Endoperoxide Synthase 1: Lower Levels in Schizophrenia and After Treatment with Antipsychotic Drugs in Conjunction with Aspirin.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Aspirin; Bipolar Disorder; B | 2018 |
New drug candidates for bipolar disorder-A nation-wide population-based study.
Topics: Adult; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bipolar Disorder; Denmark; Dru | 2019 |
A case report that suggested that aspirin's effects on valproic acid metabolism may contribute to valproic acid's inducer effects on clozapine metabolism.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Aspirin; Bipolar Disorder; Clozapine; Dose-Response R | 2013 |
Recently discovered properties of aspirin may be doubly helpful in bipolar disorders.
Topics: Aspirin; Bipolar Disorder; Humans; Models, Theoretical | 2014 |
Aspirin for prevention of cardiovascular events in bipolar disorders.
Topics: Antimanic Agents; Antipsychotic Agents; Aspirin; Bipolar Disorder; Cardiovascular Diseases; Humans | 2014 |
Aspirin, arachidonic acid and the regulation of mood.
Topics: Affect; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Arachidonic Acid; Aspirin; Bi | 2010 |
Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Aspirin; Bip | 2010 |
Aspirin does not significantly affect patients' serum lithium levels.
Topics: Aspirin; Bipolar Disorder; Female; Humans; Lithium; Lithium Carbonate; Male; Middle Aged; Psychotic | 1987 |
[Neuropsychiatry in 1973].
Topics: Aspirin; Bipolar Disorder; Dipyridamole; Heart Diseases; Humans; Hydrocephalus; Hypoxia, Brain; Isch | 1973 |